Improving diagnosis and treatments for refractory epilepsy.
Personalised treatments to improve seizure control.
Around 2% of people will develop epilepsy during their lifetime. Currently there are around 100,000 children and adults in Queensland with epilepsy. More than a third of patients don’t respond to current anti-epilepsy drugs.
This project will incorporate genomic testing into the model of care for patients with neurological disorders like refractory epilepsy.
This approach can provide patients and their families with a cause for the disorder, as well as an opportunity for better treatment choices suited to the patient.
The ultimate goal of this work is to improve the quality of care for patients and their families, and improve efficiencies in healthcare.
This is a clinical implementation project, which applies best evidence to clinical practice and is intended to become standard of care following project completion.